Abstract
Despite the extensive efforts by researchers in the study of cancer, the resultant therapeutic impacts remained limited. Consequently, cancer has persistently ranked as the top leading cause of mortality for several decades. In the recent years, the focus has shifted to recognizing the significance of the complex networks within the tumor microenvironment (TME) due to their impacts on patients’ prognosis and therapeutic effects. TME plays a crucial role in cancer progression, as it improves cancer cells survival and promotes the escape of cancer cells from immunosurveillance. Besides, the invasiveness of cancer cells is enhanced by the interplays between cellular and structural components of the TME. For instance, TME could enhance cancer progression by building a mechanical barrier that inhibits the infiltration of anti-tumoral immune cells or therapeutic agents. Even though the TME possesses both anti-tumoral and pro-tumoral immune cells, the pro-tumoral immune cells usually outnumber their counterparts in the majority of cancer patients. This immune imbalance contributes to the severe immunosuppression properties in cancer, and it is regulated by various immune cells and their respective immunomodulatory cytokines via a complex interaction. Hence, immunotherapies are developed, aiming to restore the immune balance in the TME. In this chapter, we focus on the paradoxical roles of different immune cells and how they contribute to the tumor-antagonizing or tumor-promoting effects.
This is a preview of subscription content, log in via an institution to check access.
References
Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, Brandau S, Dittmer U (2016) CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity. J Immunol 196(1):484–492. https://doi.org/10.4049/jimmunol.1403039
Albini A, Bruno A, Noonan DM, Mortara L (2018) Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 9:527. https://doi.org/10.3389/fimmu.2018.00527
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8. https://doi.org/10.3389/fphar.2017.00561
Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30(16):R921–R925. https://doi.org/10.1016/j.cub.2020.06.081
Appiya Santharam M, Dhandapani V (2019) Role of inflammatory cytokines in the initiation and progression of pancreatic cancer. In: Exploring pancreatic metabolism and malignancy. Springer, Singapore, pp 133–156
Aras S, Zaidi MR (2017) TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 117(11):1583–1591. https://doi.org/10.1038/bjc.2017.356
Bogen B, Fauskanger M, Haabeth OA, Tveita A (2019) CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models. Cancer Immunol Immunother 68(11):1865–1873. https://doi.org/10.1007/s00262-019-02374-0
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W (2018) CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18(10):635–647. https://doi.org/10.1038/s41577-018-0044-0
Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring H-U, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494(7437):361–365. https://doi.org/10.1038/nature11824
Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7(1):12150. https://doi.org/10.1038/ncomms12150
Bruni D, Angell HK, Galon J (2020) The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 20(11):662–680. https://doi.org/10.1038/s41568-020-0285-7
Cachot A, Bilous M, Liu Y-C, Li X, Saillard M, Cenerenti M, Rockinger GA, Wyss T, Guillaume P, Schmidt J, Genolet R, Ercolano G, Protti MP, Reith W, Ioannidou K, de Leval L, Trapani JA, Coukos G, Harari A, Speiser DE, Mathis A, Gfeller D, Altug H, Romero P, Jandus C (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv 7(9):eabe3348. https://doi.org/10.1126/sciadv.abe3348
Cenerenti M, Saillard M, Romero P, Jandus C (2022) The era of cytotoxic CD4 T cells. Front Immunol 13. https://doi.org/10.3389/fimmu.2022.867189
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012
Chen M-L, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 102(2):419–424. https://doi.org/10.1073/pnas.0408197102
Choi I-K, Wang Z, Ke Q, Hong M, Paul DW, Fernandes SM, Hu Z, Stevens J, Guleria I, Kim H-J, Cantor H, Wucherpfennig KW, Brown JR, Ritz J, Zhang B (2021) Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 590(7844):157–162. https://doi.org/10.1038/s41586-020-03075-w
Chong YP, Peter EP, Lee FJM, Chan CM, Chai S, Ling LPC, Tan EL, Ng SH, Masamune A, Ghafar SAA, Ismail N, Ho KL (2022) Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression. Sci Rep 12(1):12315. https://doi.org/10.1038/s41598-022-16671-9
Condamine T, Mastio J, Gabrilovich DI (2015) Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 98(6):913–922. https://doi.org/10.1189/jlb.4RI0515-204R
Conlon KC, Miljkovic MD, Waldmann TA (2019) Cytokines in the treatment of cancer. J Interf Cytokine Res 39(1):6–21. https://doi.org/10.1089/jir.2018.0019
Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A (2009) Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 206(1):51–59. https://doi.org/10.1084/jem.20081242
Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, Fitzgerald B, Foster GG, Eisenbarth SC, Zhao H, Craft J, Joshi NS (2021) Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184(25):6101–6118.e6113. https://doi.org/10.1016/j.cell.2021.11.007
Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP (2013) Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210(4):743–755. https://doi.org/10.1084/jem.20121190
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478. https://doi.org/10.1084/jem.20101876
Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11–22. https://doi.org/10.1038/nrc1252
Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234(6):8509–8521. https://doi.org/10.1002/jcp.27782
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734. https://doi.org/10.1038/nrclinonc.2017.101
Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signore A (2020) Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res 39(1):89. https://doi.org/10.1186/s13046-020-01586-y
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284. https://doi.org/10.1101/gad.314617.118
Göret N, Canbey C, Topal U, Ozkan O (2019) A review of B lymphocytes in tumour immune response. J Stem Cell Res Med 4. https://doi.org/10.15761/JSCRM.1000133
Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17(9):1025–1036. https://doi.org/10.1038/ni.3518
Habif G, Crinier A, André P, Vivier E, Narni-Mancinelli E (2019) Targeting natural killer cells in solid tumors. Cell Mol Immunol 16(5):415–422. https://doi.org/10.1038/s41423-019-0224-2
Haura EB, Turkson J, Jove R (2005) Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2(6):315–324. https://doi.org/10.1038/ncponc0195
HladĂková K, KouckĂ˝ V, BouÄŤek J, Laco J, Grega M, Hodek M, ZábrodskĂ˝ M, Vošmik M, Rozkošová K, Vošmiková H, ÄŚelakovskĂ˝ P, Chrobok V, Ryška A, Ĺ pĂšek R, Fialová A (2019) Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8<sup>+</sup> T cells. J Immunother Cancer 7(1):261. https://doi.org/10.1186/s40425-019-0726-6
Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, Slater EP, Bartsch JW, Bauer C, Lauth M (2020) The immune microenvironment in pancreatic cancer. Int J Mol Sci 21(19):7307. https://doi.org/10.3390/ijms21197307
Janeway CA, Travers P, Walport M, Shlomchik MJ (2001) Immunology: the immune system in health and disease. Garland Science, New York
Janjic BM, Kulkarni A, Ferris RL, Vujanovic L, Vujanovic NL (2022) Human B cells mediate innate anti-cancer cytotoxicity through concurrent engagement of multiple TNF superfamily ligands. Front Immunol 13:837842. https://doi.org/10.3389/fimmu.2022.837842
Jeong S, Jang N, Kim M, Choi IK (2023) CD4(+) cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Rep 56(2):140–144. https://doi.org/10.5483/BMBRep.2023-0014
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558. https://doi.org/10.1038/s41591-018-0136-1
Johnson BA, Yarchoan M, Lee V, Laheru DA, Jaffee EM (2017) Strategies for increasing pancreatic tumor immunogenicity. Clin Cancer Res 23(7):1656. https://doi.org/10.1158/1078-0432.CCR-16-2318
Jorgovanovic D, Song M, Wang L, Zhang Y (2020) Roles of IFN-Îł in tumor progression and regression: a review. Biomark Res 8(1):49. https://doi.org/10.1186/s40364-020-00228-x
Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jafri A (2018) Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med 16(1):242. https://doi.org/10.1186/s12967-018-1611-7
Kalia V, Sarkar S (2018) Regulation of effector and memory CD8 T cell differentiation by IL-2 – a balancing act. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.02987
Kim H-J, Cantor H (2014) CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2(2):91–98. https://doi.org/10.1158/2326-6066.cir-13-0216
Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD (2013) Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235–244. https://doi.org/10.1158/2326-6066.cir-13-0068
Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, McEvoy J, Roussel MF, Dyer MA, Qualls JE, Murray PJ (2015) TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep 12(11):1902–1914. https://doi.org/10.1016/j.celrep.2015.08.033
Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9(4):405–410. https://doi.org/10.1016/j.coph.2009.06.006
Kravtsov DS, Erbe AK, Sondel PM, Rakhmilevich AL (2022) Roles of CD4+ T cells as mediators of antitumor immunity. Front Immunol 13. https://doi.org/10.3389/fimmu.2022.972021
Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905–6913. https://doi.org/10.4049/jimmunol.1100274
Laha D, Grant R, Mishra P, Nilubol N (2021) The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. Front Immunol 12. https://doi.org/10.3389/fimmu.2021.656908
Lan T, Chen L, Wei X (2021) Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells 10(1). https://doi.org/10.3390/cells10010100
Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Han NI, Yoon SK (2019) Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 9(1):3260. https://doi.org/10.1038/s41598-019-40078-8
Lei X, Lei Y, Li J-K, Du W-X, Li R-G, Yang J, Li J, Li F, Tan H-B (2020) Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett 470:126–133. https://doi.org/10.1016/j.canlet.2019.11.009
Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP (2008) Low levels of tumor necrosis factor α increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 69(1):338–348. https://doi.org/10.1158/0008-5472.can-08-1565
Li C, Jiang P, Wei S, Xu X, Wang J (2020) Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer 19(1):116. https://doi.org/10.1186/s12943-020-01234-1
Lin W, Singh V, Springer R, Choonoo G, Gupta N, Patel A, Frleta D, Zhong J, Owczarek T, Decker C, Macdonald L, Murphy A, Thurston G, Mohrs M, Ioffe E, Lu Y-F (2023) Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice. Commun Biol 6(1):447. https://doi.org/10.1038/s42003-023-04812-3
Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178(5):2883–2892. https://doi.org/10.4049/jimmunol.178.5.2883
Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, Hua J, Yu X, Shi S (2019) The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Mol Cancer 18(1):184. https://doi.org/10.1186/s12943-019-1117-9
Maimela NR, Liu S, Zhang Y (2019) Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J 17:1–13. https://doi.org/10.1016/j.csbj.2018.11.004
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416. https://doi.org/10.1038/nrclinonc.2016.217
Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23(1):64. https://doi.org/10.1186/s12935-023-02902-0
Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD, O’Donoghue DP, Mulcahy HE, Ryan EJ, O’Sullivan JN (2011) Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 6(11):e27944. https://doi.org/10.1371/journal.pone.0027944
Moghbeli M, Khedmatgozar H, Yadegari M, Avan A, Ferns GA, Ghayour Mobarhan M (2021) Chapter Five – Cytokines and the immune response in obesity-related disorders. In: Makowski GS (ed) Advances in clinical chemistry, vol 101. Elsevier, Amsterdam, pp 135–168
Mojic M, Takeda K, Hayakawa Y (2018) The dark side of IFN-Îł: its role in promoting cancer Immunoevasion. Int J Mol Sci 19(1):89
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, SĂ©gui B (2019) The TNF paradox in cancer progression and immunotherapy. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.01818
Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M (2000) B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192(4):475–482. https://doi.org/10.1084/jem.192.4.475
Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14):5728–5739. https://doi.org/10.1158/0008-5472.can-09-4672
Nakamura K, Smyth MJ (2020) Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol 17(1):1–12. https://doi.org/10.1038/s41423-019-0306-1
Narayanan S, Kawaguchi T, Peng X, Qi Q, Liu S, Yan L, Takabe K (2019) Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer. Sci Rep 9(1):13455. https://doi.org/10.1038/s41598-019-49878-4
Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P (2021) The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers 13(9). https://doi.org/10.3390/cancers13092053
Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, Liu X, **ao L, Chen X, Wan B, Chin YE, Zhang JZ (2013) Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med 19(3):322–328. https://doi.org/10.1038/nm.3085
Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71(10):3505–3515. https://doi.org/10.1158/0008-5472.can-10-4316
Ou W, Thapa RK, Jiang L, Soe ZC, Gautam M, Chang J-H, Jeong J-H, Ku SK, Choi H-G, Yong CS, Kim JO (2018) Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release 281:84–96. https://doi.org/10.1016/j.jconrel.2018.05.018
Poncette L, Bluhm J, Blankenstein T (2022) The role of CD4 T cells in rejection of solid tumors. Curr Opin Immunol 74:18–24. https://doi.org/10.1016/j.coi.2021.09.005
Raskov H, Orhan A, Christensen JP, Gögenur I (2021) Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124(2):359–367. https://doi.org/10.1038/s41416-020-01048-4
Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD (2018) Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18(1):5–18. https://doi.org/10.1038/nri.2017.97
Richardson JR, Schöllhorn A, Gouttefangeas C, Schuhmacher J (2021) CD4+ T cells: multitasking cells in the duty of cancer immunotherapy. Cancers 13(4). https://doi.org/10.3390/cancers13040596
Rossin A, Miloro G, Hueber AO (2019) TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers 11(5). https://doi.org/10.3390/cancers11050639
Sarvaria A, Madrigal JA, Saudemont A (2017) B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14(8):662–674. https://doi.org/10.1038/cmi.2017.35
Savage PA, Leventhal DS, Malchow S (2014) Sha** the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 259(1):245–258. https://doi.org/10.1111/imr.12166
Savage PA, Klawon DEJ, Miller CH (2020) Regulatory T cell development. Annu Rev Immunol 38(1):421–453. https://doi.org/10.1146/annurev-immunol-100219-020937
Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64(4):419–427. https://doi.org/10.1007/s00262-014-1651-7
Seo YD, Pillarisetty VG (2017) T-cell programming in pancreatic adenocarcinoma: a review. Cancer Gene Ther 24(3):106–113. https://doi.org/10.1038/cgt.2016.66
Serroukh Y, Gu-Trantien C, Hooshiar Kashani B, Defrance M, Vu Manh TP, Azouz A, Detavernier A, Hoyois A, Das J, Bizet M, Pollet E, Tabbuso T, Calonne E, van Gisbergen K, Dalod M, Fuks F, Goriely S, Marchant A (2018) The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes. elife 7. https://doi.org/10.7554/eLife.30496
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O’Byrne K, Kulasinghe A (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044–3060
Śledzińska A, Vila de Mucha M, Bergerhoff K, Hotblack A, Demane DF, Ghorani E, Akarca AU, Marzolini MAV, Solomon I, Vargas FA, Pule M, Ono M, Seddon B, Kassiotis G, Ariyan CE, Korn T, Marafioti T, Lord GM, Stauss H, Jenner RG, Peggs KS, Quezada SA (2020) Regulatory T cells restrain interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by CD4(+) T cells. Immunity 52(1):151–166.e156. https://doi.org/10.1016/j.immuni.2019.12.007
Speiser DE, Chijioke O, Schaeuble K, Münz C (2023) CD4+ T cells in cancer. Nat Cancer 4(3):317–329. https://doi.org/10.1038/s43018-023-00521-2
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and T<sub>regs</sub> in the melanoma tumor microenvironment is driven by CD8<sup>+</sup> T cells. Sci Transl Med 5(200):200ra116-200ra116. https://doi.org/10.1126/scitranslmed.3006504
Takeuchi A, Badr Mel S, Miyauchi K, Ishihara C, Onishi R, Guo Z, Sasaki Y, Ike H, Takumi A, Tsuji NM, Murakami Y, Katakai T, Kubo M, Saito T (2016) CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J Exp Med 213(1):123–138. https://doi.org/10.1084/jem.20150519
Tan R, Nie M, Long W (2022) The role of B cells in cancer development. Front Oncol 12. https://doi.org/10.3389/fonc.2022.958756
Tay RE, Richardson EK, Toh HC (2021) Revisiting the role of CD4+ T cells in cancer immunotherapy – new insights into old paradigms. Cancer Gene Ther 28(1):5–17. https://doi.org/10.1038/s41417-020-0183-x
Tcyganov E, Mastio J, Chen E, Gabrilovich DI (2018) Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol 51:76–82. https://doi.org/10.1016/j.coi.2018.03.009
Thornton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188(2):287–296. https://doi.org/10.1084/jem.188.2.287
Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. Nat Rev Clin Oncol 16(6):356–371. https://doi.org/10.1038/s41571-019-0175-7
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954
Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DAA (2016) Interleukin-35 limits anti-tumor immunity. Immunity 44(2):316–329. https://doi.org/10.1016/j.immuni.2016.01.013
Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23(2):39. https://doi.org/10.1208/s12248-021-00574-0
Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108(1):253–261. https://doi.org/10.1182/blood-2005-11-4567
Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66(8):4488–4495. https://doi.org/10.1158/0008-5472.can-05-4217
Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim S-H, Egwuagu CE (2014) Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20(6):633–641. https://doi.org/10.1038/nm.3554
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, Li J, Yao H, Chen K (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 12(10):11149–11165. https://doi.org/10.1002/cam4.5698
West EE, ** HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R (2013) PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 123(6):2604–2615. https://doi.org/10.1172/jci67008
What Is Cancer? (2021, October 11). Retrieved from https://www.cancer.gov/about-cancer/understanding/what-is-cancer
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271–275. https://doi.org/10.1126/science.1160062
Winstead E (2022) Opdualag becomes first FDA-approved immunotherapy to target LAG-3. Retrieved from National Cancer Institute
Wörmann SM, Diakopoulos KN, Lesina M, Algül H (2014) The immune network in pancreatic cancer development and progression. Oncogene 33(23):2956–2967. https://doi.org/10.1038/onc.2013.257
Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661–674. https://doi.org/10.1016/j.csbj.2019.03.006
Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651–658. https://doi.org/10.7150/ijbs.7.651
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z (2018a) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19(7):723–732. https://doi.org/10.1038/s41590-018-0132-0
Zhang Y, Wu L, Li Z, Zhang W, Luo F, Chu Y, Chen G (2018b) Glycocalyx-mimicking nanoparticles improve anti-PD-L1 cancer immunotherapy through reversion of tumor-associated macrophages. Biomacromolecules 19(6):2098–2108. https://doi.org/10.1021/acs.biomac.8b00305
Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, Sun J, Zheng M, Yang X (2023) Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res 11(1):28. https://doi.org/10.1186/s40364-023-00460-1
Zhou Q, Tao X, **a S, Guo F, Pan C, **ang H, Shang D (2020) T lymphocytes: a promising immunotherapeutic target for pancreatitis and pancreatic cancer? Front Oncol 10:382–382. https://doi.org/10.3389/fonc.2020.00382
Acknowledgments
We would like to take this opportunity to thank Ahmie Zamora for her valuable feedback on the text during its composition and revising stages.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure of Potential Conflicts of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chong, Y.P., Walsh, J.E., Ho, K.L. (2024). The Paradoxical Role of Immune Response in Cancer Microenvironment. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2024_273
Download citation
DOI: https://doi.org/10.1007/16833_2024_273
Published:
Publisher Name: Springer, Cham